Search

Search Constraints

You searched for: Author/Creator Earl, Helena

Search Results

1. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Issue 10191 (29th June 2019)

2. A nested cohort study of 6, 248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities. Issue 1 (December 2015)

3. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Issue 7 (July 2017)

4. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio‐Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio‐Oncology Society. (6th August 2020)

5. Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative. Issue 3 (February 2015)

6. Common germline polymorphisms associated with breast cancer-specific survival. Issue 1 (December 2015)

7. Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. Issue 1 (December 2016)

8. Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer. Issue 6 (July 2015)

9. Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study. Issue 6 (1st July 2015)